Autoimmune rheumatic manifestations in a cohort of Egyptian COVID-19 patients … Original Research Article … |
The Egyptian Journal of Immunology E-ISSN (2090-2506) Volume 32 (1), January 2025 Pages: 105 – 115 www.Ejimmunology.org https://doi.org/10.55133/eji.320110 |
|
Dalia A. ElSherbiny, Samah A. El Bakry, Sara A. Abd El Rahman, and Amr M. Hawwash |
Department of Internal Medicine, Rheumatology & Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | Corresponding author: Dalia A. ElSherbiny, Department of Internal Medicine, Rheumatology & Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Email: dalia_elsherbiny@hotmail.com |
Abstract
The coronavirus disease 2019 (COVID-19) pandemic had significant global health impact. Like systemic autoimmune diseases, COVID-19 may manifest with systemic and heterogenous clinical presentations. This study aimed to evaluate the prevalence of autoimmune rheumatic manifestations among a cohort of Egyptian patients with COVID-19 infection. The study included 90 adult confirmed COVID-19 patients as determined by the polymerase chain reaction test. They were subjected to the following assessments: detailed medical history, full clinical and rheumatological examination, routine laboratory investigations, a panel of autoimmune markers, and high-resolution computed tomography chest. Then the patients studied were divided according to the positivity of autoimmune markers into positive and negative groups. According to the COVID-19 disease severity, patients were divided into mild, moderate, severe, and critical groups. The mean age of the study population was 54.60 ± 10.72 years, and 53.3% of them were females and 46.7% males. Of the patients studied 13.3% had positive antinuclear antibodies (ANA), 15.6% positive for rheumatoid factor (RF), 8.9% positive for anticardiolipin (ACL) IgM, and 5.6% positive for ACL IgG. The autoimmune markers were not statistically different however, all cases with positive ANA were present among severe and critical COVID-19 cases. All cases with positive RF, ACL IgM, or ACL IgG were found among moderate, severe, and critical patients. In conclusion, COVID-19 disease is associated with variable autoimmune manifestations. Autoimmune rheumatic manifestations, either clinical or autoimmune markers, are more evident in severe and critical COVID-19 cases. COVID-19 patients with positive ANA or RF are more likely to develop cutaneous, musculoskeletal, and vascular manifestations.
Keywords:
Autoimmune; COVID-19; antinuclear antibodies; rheumatoid factor; anticardiolipin; high-resolution computed tomography.
Date received:
18 May 2024; accepted: 01 April 2025
PMID:
39804136
Full Text